Still waiting for the FDA to tell Pharma what we can do in Social Media? Folks, we already have our guidelines. Reading an old article last night (note: from Jan 2014) made me realize some of the real reasons behind Pharma’s struggle with social media – and it’s not because of the FDA or lack of guidance. While theContinue reading Pharma, We Already Have Our FDA Social Media Guidelines
Social Media is not to be used merely as a channel for distribution, nor to drive to your website or run contests to get people to “Like” your page or follow your handle.
It’s known as “Social Media” because it all started with being social. Connecting with friends, family and acquaintances. Brands suddenly became involved in what were Social Networks, most unable to grasp the nature of the medium from the beginning. Many have adapted, others still fall far behind. Continue reading Don’t Just Use Social – BE SOCIAL (and why that’s okay for Pharma)
In my eyes, we’ve only uncovered the tip of the iceberg for health and mobile, it has always just been a matter of avoiding the giant block of ambiguous ice that lives underneath that tip – but with the proper navigation, the opportunity for innovation and success is unlimited. The caution comes mostly in the fear of riskContinue reading Pharma Mobile Apps Are Not Dead and Kudos Sanofi, But More Can Be Done
Facebook’s recent newsfeed algorithm change has presented an indirect a wake-up call for pharma: it’s time to learn how to be social. It’s more imperative than ever to garner engagement on your posts, so adapt accordingly. But why is it that pharma has struggled to be successful in what may arguably be one of the mostContinue reading HEY PHARMA! Time to Embrace Being Social.
Translation: What aspects of social media is pharma responsible for and the process for interacting in real-time while adhering to FDA postmarketing submission guidelines. On the path to releasing full guidance for pharma promotional activities in social media in July 2014, yesterday, the Food and Drug Administration (FDA) released draft guidance for comment, specific toContinue reading Explained: New FDA Guidance on Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media
One month ago, we organized an event known as Pioneers in Digital Health, a gathering of marketing and healthcare communications leaders for a forum meant to explore the latest and greatest in healthcare and digital. While there were some great key takeaways we heard from our attendees, I felt that there was a core message thatContinue reading Digital Pioneers – What Did We Learn?
First, let’s note that this document does not provide any new regulations regarding the industry’s use of digital and social media. Instead, these guidelines respond to requests that the FDA clarify the specific regulations for placement, size and prominence of brand names vs. generic names appearing in promotional advertisements (print, audio/video and online). Below isContinue reading New FDA Guidance Clarifies Brand & Generic Name Inclusion in Print, Broadcast and Online Media
Includes use of Digital/Social for this Purpose The FDA quietly issued a 15-page draft guidance on December 28th 2011, outlining how manufacturers could respond to solicited and unsolicited requests for off-label information. The draft addresses both private requests, such as one-on-one communications, and requests made in public forums – such as conferences, product websites, blogs,Continue reading FDA Issues Guidance for Responding to Requests for Off- Label Information Online